Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats

被引:59
作者
Westerlind, KC
Gibson, KJ
Malone, P
Evans, GL
Turner, RT
机构
[1] AMC, Ctr Canc Res, Denver, CO 80214 USA
[2] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
关键词
D O I
10.1359/jbmr.1998.13.6.1023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of 17 beta-estradiol and the important estrogen metabolites, 2-hydroxyestrone (2-OHE1) and 16 alpha-hydroxyestrone (16 alpha-OHE1) on bone, mammary gland, and uterine histology, and on blood cholesterol were investigated in ovariectomized growing rats. Rats were treated with 200 mu g/kg of body weight/day of each of the test compounds for 3 weeks, Ovariectomy resulted in uterine and mammary gland atrophy, increased body weight, bone turnover and tibia growth, and hypercholesterolemia. 17 beta-estradiol treatment prevented these changes, with the exception that this high dose of estrogen did not prevent hypercholesterolemia. 2-OHE1 had no effect on any of the measurements. 16 alpha-OHE1 resulted in bone measurements that did not differ from the 17 beta-estradiol-treated rats and prevented the increase in serum cholesterol, In contrast, 16 alpha-OHE1 resulted in increases in uterine weight, uterine epithelial cell height, and mammary gland cell proliferation that were significantly less than the 17 beta-estradiol treatment. These findings demonstrate that 16 alpha-hydroxylation of estrone results in tissue-selective estrogen agonistic activity, whereas 2-hydroxylation resulted in no measured activity. Furthermore, they suggest that factors that modulate the synthesis of these metabolites could selectively influence estrogen target tissues.
引用
收藏
页码:1023 / 1031
页数:9
相关论文
共 44 条
[11]   Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia [J].
Evans, GL ;
Bryant, HU ;
Magee, DE ;
Turner, RT .
ENDOCRINOLOGY, 1996, 137 (10) :4139-4144
[12]   BIOLOGICAL PROPERTIES OF 16 ALPHA-HYDROXYESTRONE - IMPLICATIONS IN ESTROGEN PHYSIOLOGY AND PATHO-PHYSIOLOGY [J].
FISHMAN, J ;
MARTUCCI, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 51 (03) :611-615
[13]   LONG-TERM ADJUVANT TAMOXIFEN IN EARLY BREAST-CANCER - EFFECT ON BONE-MINERAL DENSITY IN POSTMENOPAUSAL WOMEN [J].
FORNANDER, T ;
RUTQVIST, LE ;
SJOBERG, HE ;
BLOMQVIST, L ;
MATTSSON, A ;
GLAS, U .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :1019-1024
[14]  
GALLAGHER JC, 1996, OSTEOPOROSIS
[15]   Ascorbic acid alters collagen integrins in bone culture [J].
Ganta, DR ;
McCarthy, MB ;
Gronowicz, GA .
ENDOCRINOLOGY, 1997, 138 (09) :3606-3612
[16]  
HODGE J, 1995, J BONE MINER RES, V10, pS444
[17]   Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction [J].
Hoyland, JA ;
Mee, AP ;
Baird, P ;
Braidman, IP ;
Mawer, EB ;
Freemont, AJ .
BONE, 1997, 20 (02) :87-92
[18]   Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats [J].
Jimenez, MA ;
Magee, DE ;
Bryant, HU ;
Turner, RT .
ENDOCRINOLOGY, 1997, 138 (05) :1794-1800
[19]  
Kabat GC, 1997, CANCER EPIDEM BIOMAR, V6, P505
[20]   DROLOXIFENE, A NEW ESTROGEN ANTAGONIST AGONIST, PREVENTS BONE LOSS IN OVARIECTOMIZED RATS [J].
KE, HZ ;
SIMMONS, HA ;
PIRIE, CM ;
CRAWFORD, DT ;
THOMPSON, DD .
ENDOCRINOLOGY, 1995, 136 (06) :2435-2441